A major announcement was made recently by Otsuka Pharmaceutical Co., Ltd. that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The FDA's goal for reviewing a drug with Priority Review status is six months from the NDA submission date. The FDA target action date (PDUFA date) for this NDA is September 1, 2013.
The Foundation funded early preclinical animal testing of tolvaptan, the precursor to the human clinical trials that showed positive results in slowing the progression of PKD. The results of the Phase III clinical trial results that formed the basis of the regulatory filing were published in the New England Journal of Medicine in November.
If approved, tolvaptan will become the first pharmaceutical therapy for patients with ADPKD.
View or download the official press release from Otsuka Pharmaceutical Co., Ltd.Visit Otsuka's websiteRead an earlier announcement about the results of the Phase III clinical trialLearn how to submit your testimonial for the FDA Advisory Committee's review of tolvaptan
2000 Daniel Island Drive, Charleston SC 29492
Phone: 800.443.9441 | Fax: firstname.lastname@example.org
©2013, PKD Foundation ·The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.
Subscribe to PKDnews, our free monthly newsletter
Free Info Packet
Terms & Conditions
PKD Will Not Beat Me
International: Australia Canada France Germany Italy Japan United Kingdom